- Livin, also known as ML‑IAP (Melanoma Inhibitor of Apoptosis Protein), is a member of the IAP family, where it functions alongside XIAP, cIAP1 and cIAP2 to regulate apoptosis and cell survival. Livin is unique among mammalian IAPs because it exists in two splice variants—Livin‑α and Livin‑β—which differ in their anti‑apoptotic potency and substrate specificity. Livin is strongly associated with tumour progression, immune evasion and resistance to therapy, making it a major focus in cancer biology.
- Structurally, Livin contains a single BIR (Baculovirus IAP Repeat) domain and a C‑terminal RING finger ubiquitin ligase domain. The BIR domain binds and inhibits caspase‑3, caspase‑7 and caspase‑9, suppressing both intrinsic and extrinsic apoptotic pathways. Livin‑α and Livin‑β differ in their ability to inhibit caspases, with Livin‑β generally showing stronger anti‑apoptotic activity. This caspase inhibition allows tumour cells to survive under conditions that would normally trigger apoptosis.
- The RING domain of Livin contributes to its regulatory versatility by functioning as an E3 ubiquitin ligase. Livin can ubiquitinate pro‑apoptotic proteins such as Smac/DIABLO, targeting them for degradation and further reinforcing its anti‑apoptotic effect. This dual mechanism—caspase inhibition and ubiquitination—makes Livin a powerful survival factor in cancer cells.
- Livin is highly expressed in melanoma, lung cancer, bladder cancer, colorectal cancer and several haematological malignancies. Its expression correlates with tumour aggressiveness, metastasis and poor prognosis. Because Livin is rarely expressed in most normal adult tissues, it is considered a tumour‑specific survival factor. This selective expression pattern makes Livin an attractive therapeutic target.
- One of the most interesting features of Livin is its ability to undergo proteolytic cleavage under strong apoptotic stimuli. Cleaved Livin loses its anti‑apoptotic function and instead becomes pro‑apoptotic, amplifying cell death. This functional switch distinguishes Livin from other IAPs and suggests a built‑in fail‑safe mechanism that prevents uncontrolled survival signalling.
- Livin also modulates immune responses. By suppressing apoptosis in tumour cells, Livin contributes to immune evasion and resistance to cytotoxic T‑cell killing. Its expression influences tumour microenvironment dynamics and may affect responses to immunotherapy.
- In summary, Livin (ML‑IAP) is a unique dual‑function IAP that inhibits caspases, ubiquitinates pro‑apoptotic proteins and supports tumour survival. Its splice variants, tumour‑specific expression and ability to switch from anti‑apoptotic to pro‑apoptotic roles make Livin a key regulator in cancer biology and a promising therapeutic target.
